Sympa Health Selected for Organon META's Women's Health Accelerator 2025–2026

Recognised Among Innovators Shaping the Future of Women's Health

We are proud to announce that Sympa Health has been shortlisted for Organon META's Women's Health Accelerator Program 2025–2026 - a highly competitive initiative bringing together startups and innovators advancing access, innovation, and impact across women's health.

About Organon and the Accelerator

Organon is a global healthcare company with a singular focus on women's health, biosimilars, and established medicines. Its META Women's Health Accelerator is designed to identify and support the most promising solutions emerging across the region - and to actively shape the next generation of women's healthcare.

Being shortlisted alongside a select group of innovators from the MENA region and beyond reflects the growing recognition that FemTech and digital health solutions have a critical role to play in closing longstanding gaps in women's care.

What This Means for Sympa Health

For us, this is more than an accolade. Selection into a programme led by one of the world's most dedicated women's health organisations affirms that the problem we are solving - making endometriosis care more accessible, personalised, and science-backed - is recognised as urgent and strategically important on a global scale.

The accelerator will provide Sympa Health with the opportunity to deepen our understanding of diverse women's health markets, connect with leading experts and stakeholders, and accelerate the development of our platform.

Building Towards Real Impact

Endometriosis affects an estimated 190 million women worldwide, yet diagnosis still takes an average of eight years. The support of programmes like Organon META's Accelerator brings us one step closer to changing that - for women in Poland, the UK, the MENA region, and beyond.

We look forward to sharing more about this journey in the weeks ahead.

‍